Biopharmaceuticals outfit Enzon Pharmaceuticals
Most of the revenue boost came from antifungal Abelcet -- a $360 million acquisition from Elan
Sales for the company's three other products were also up a robust 52% to $10 million.
Royalties for hepatitus C drug PEG-Intron, manufactured and marketed by Schering-Plough
For the quarter, R&D spending increased 60% to $6.6 million. That was expected -- and good for the long-term health of Enzon. On the other hand, SG&A, up 280%, and cost of sales and manufacturing, up 435%, need attention if profits are to recover.
The good of Enzon is that it's profitable. Abelcet brought manufacturing assets and a sales force -- and the promise that profits will continue. It also helped the company's total debt balloon to $400 million -- an extremely high 2.6 long-term debt-to-equity ratio. This debt could be a real burden if profitability is not maintained.
Despite its promising product pipeline, PEG-Intron and Abelcet are the heart of Enzon. With PEG-Intron, as expected, seeing sales erosion, Abelcet needs to continue gaining market share to return the hefty investment Enzon has financed with debt.
Either way, there seems little, near term, to move this stock.
You can reach W.D. Crotty at Hawaii-Fool@hawaii.com .
More from The Motley Fool
Wall Street Is Clueless on Facebook
Long-term investors should trust Mark Zuckerberg and applaud recent timeline changes.
When Will Self-Driving Cars Be on the Market?
This week, we talk about what the Consumer Electronics Show revealed about the progress toward autonomous vehicles, plus the latest on BP and GE.
Better Buy: Himax Technologies, Inc. vs. Cypress Semiconductor
A strong case can be made for both semiconductor upstarts, but one holds the edge as the better buy.